Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Hum Pathol. 2011 Sep;42(9):1213-20. doi: 10.1016/j.humpath.2010.12.006. Epub 2011 Mar 21.
The classification of follicular thyroid neoplasms requires surgical resection for histologic evaluation of malignancy. Because variable clinical behavior exists, genomic expression profiling may lead to the identification of novel markers that facilitate better biologic classification. We performed for the first time gene expression analysis on clinically aggressive and nonaggressive follicular carcinomas (FCs) from patients for whom long-term follow-up data were available. We examined matched fresh-frozen tissue from 15 histopathologically diagnosed follicular carcinomas (7 patients with documented distant metastasis and/or death from disease and 8 patients without recurrence). For categorical comparison, we analyzed 4 follicular adenomas (FAs). The biologic control comprised 11 normal thyroid tissue specimens. High-quality RNA was extracted from the tissues, labeled, and hybridized to an Affymetrix (Santa Clara, CA) oligonucleotide microarray (HG-U133A). With the exceptions of 1 follicular adenoma and 1 follicular carcinoma, unsupervised hierarchical cluster analysis revealed 2 distinct groups--one containing normal thyroid tissue and follicular adenomas and another containing follicular carcinomas. We identified 421 genes that were differentially expressed between histologically normal thyroid tissues and all follicular neoplasms (P < 0.01; fold-change >2), 94 genes that distinguished follicular carcinomas from follicular adenomas (including PBP and CKS2), and 4 genes that distinguished aggressive follicular carcinomas from nonaggressive follicular carcinomas (NID2, TM7SF2, TRIM2, and GLTSCR2). Comparative genomic groupings identified differentially expressed genes that may lead to better classification of follicular thyroid neoplasms. Such genes may be used in future prospective validation studies to establish clinically useful and complementary diagnostic markers.
滤泡性甲状腺肿瘤的分类需要进行手术切除,以便对恶性肿瘤进行组织学评估。由于存在不同的临床行为,基因组表达谱分析可能会发现有助于更好地进行生物学分类的新标记物。我们首次对具有长期随访数据的侵袭性和非侵袭性滤泡性癌(FC)患者的临床样本进行了基因表达分析。我们研究了 15 例组织病理学诊断为滤泡性癌的患者(7 例有明确的远处转移和/或死于疾病,8 例无复发)的新鲜冷冻组织。为了进行分类比较,我们分析了 4 例滤泡性腺瘤(FA)。生物学对照包括 11 例正常甲状腺组织标本。从组织中提取高质量的 RNA,进行标记并与 Affymetrix(圣克拉拉,CA)寡核苷酸微阵列(HG-U133A)杂交。除了 1 例滤泡性腺瘤和 1 例滤泡性癌外,无监督层次聚类分析显示 2 个不同的组-一个包含正常甲状腺组织和滤泡性腺瘤,另一个包含滤泡性癌。我们发现 421 个基因在组织学正常甲状腺组织和所有滤泡性肿瘤之间表达差异(P<0.01;倍数变化>2),94 个基因区分滤泡性癌与滤泡性腺瘤(包括 PBP 和 CKS2),4 个基因区分侵袭性滤泡性癌与非侵袭性滤泡性癌(NID2、TM7SF2、TRIM2 和 GLTSCR2)。比较基因组分组确定了可能导致滤泡性甲状腺肿瘤更好分类的差异表达基因。这些基因可用于未来的前瞻性验证研究,以建立具有临床应用价值和互补性的诊断标记物。